Phases, active trials: Phase 1: 55, Phase 2: 77, Phase 3: 94, Other: 30
Roche and its US subsidiary Genentech operate one of the deepest oncology and immunology pipelines in the industry. Their PD-L1 checkpoint inhibitor Tecentriq (atezolizumab) anchors a broad combination program across solid tumors. In hematology, obinutuzumab, polatuzumab vedotin, and CD20xCD3 bispecific antibodies (mosunetuzumab, glofitamab) represent a comprehensive B-cell malignancy platform. In neuroscience, Ocrevus (ocrelizumab) for multiple sclerosis and the Alzheimer's pipeline (gantenerumab follow-ons) drive significant clinical activity. Roche's bispecific antibody platform is among the industry's most prolific, generating multiple new trials annually.
- Oncology (hematology, solid tumors)
- Neuroscience (MS, Alzheimer's)
- Immunology / ophthalmology
- Bispecific antibodies
- Blood cancers / lymphoma
- Tecentriq (atezolizumab): PD-L1 checkpoint inhibitor
- Ocrevus (ocrelizumab): multiple sclerosis
- Polivy (polatuzumab vedotin): DLBCL ADC
- Lunsumio (mosunetuzumab): CD20xCD3 bispecific
- Columvi (glofitamab): CD20xCD3 bispecific
- Faricimab: bispecific ophthalmology (AMD, DME)
A primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants… NCT07342114 | Primary completion moved at least 3 years 5 months later Primary endpoint added | Active, Not Recruiting |
32 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or… NCT04770896 | Oct 14, 2026 · Estimated | Phase 3 |
23 more on the Completions page. See the calendar →
Monitor the Roche / Genentech pipeline daily
Get a daily digest when Roche / Genentech registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| Breast Cancer | 14 |
| Multiple Sclerosis | 11 |
| Non-Small Cell Lung Cancer | 8 |
| Diabetic Macular Edema | 7 |
| Multiple Myeloma | 7 |
| Healthy Volunteers | 6 |
| Neovascular Age-related Macular Degeneration | 6 |
| Obesity or Overweight | 6 |
Roche consistently generates the highest volume of new bispecific antibody trial registrations in hematology. Their oncology-neuroscience breadth means new trials span many indication categories, a Roche watchlist captures programs across lymphoma, MS, and ophthalmology simultaneously.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Roche / Genentech's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: Roche / Genentech may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Roche / Genentech pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| A Study of Subcutaneously Administered RO7845860 in Participants With Relapsing… NCT07749157 | Not Yet Recruiting | Primary endpoint(s) modified | 2026-10-10 |
| A Study to Assess Treatment Patterns and Treatment Adherence in Early… NCT07527741 | Recruiting | Completion pushed from May 31, 2028 to Oct 31, 2028 | 2026-10-09 |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and… NCT05503264 | Active, Not Recruiting | Trial sites reduced: 77 → 56 locations | 2026-10-09 |
| A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants… NCT06096779 | Active, Not Recruiting | Trial sites reduced: 59 → 54 locations | 2026-10-09 |
| A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in… NCT06903065 | Active, Not Recruiting | Final enrollment: 56 participants (planned 50) | 2026-10-09 |
Each trial page shows every change DataLookout has recorded for that trial.